A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112: A First in Class p53-MDM2 Antagonist, in Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocitic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL)
Although precision therapy for individual patients remains limited, combination therapy has the potential to enhance treatment efficacy while potentially reducing reliance on highly toxic chemotherapy (24)
The results are the strongest efficacy reported to date, the firm added
Nat Microbiol 5 , 883884 (2020)
Choose PT-141 if: Sexual function is your only goal desire, arousal, or ED Safety matters you want an FDA-approved, clinically tested peptide You want on-demand use take it only when needed You don't want tanning PT-141 won't change your skin color Nausea is a concern PT-141's nausea profile is significantly milder You have mole concerns PT-141 doesn't affect melanocytes Choose MT-2 if: You want tanning as the primary goal with sexual effects as a bonus You want both tanning AND sexual enhancement MT-2 delivers both Cost is a priority MT-2 is generally cheaper per vial You're comfortable with unregulated products and accept the additional risk You've had a dermatological baseline and will monitor moles regularly Consider Neither if: You have melanoma history avoid MT-2
We tested the heterogeneity of meta-analysis results by using the Cochrane Q test and quantified it as I 2 values and the between-study variance 2
